RegulatoryCompany release

Eledon wins FDA IND clearance and Fast Track for tegoprubart as Phase 3 kidney trial nears

🇺🇸 Eledon Pharmaceuticals, Inc. (ELDN) · Thu 12 Nov 2026

Eledon reports Q3 2026 results, with US regulatory milestones in islet cell and kidney transplantation and $69.7 million in cash funding operations into Q2 2027.

Eledon Pharmaceuticals reported its third-quarter 2026 results on 12 November, highlighting two US regulatory steps for its transplant candidate tegoprubart.

The FDA cleared an investigational new drug (IND) application for a registrational-path study of tegoprubart in islet cell transplantation for type 1 diabetes. The agency also granted Fast Track designation to the drug for preventing rejection in kidney transplantation.

Eledon said it plans to start the Phase 3 LEGACY trial in kidney transplantation in the fourth quarter of 2026. The study is expected to enrol about 600 patients.

On finances, the company reported $69.7 million in cash. It expects this to fund operations into the second quarter of 2027.

Context: Fast Track is an FDA programme intended to speed development and review of drugs for serious conditions with unmet need, and it allows more frequent interaction with the agency.

What it means for your team

  • Fast Track status for kidney transplant rejection prevention may open the way to more frequent FDA interaction as Eledon moves into Phase 3.
  • The islet cell IND signals a second potential registrational pathway for tegoprubart, in type 1 diabetes.
  • Teams tracking transplant immunosuppression should watch the start of the roughly 600-patient LEGACY trial, due in Q4 2026.
  • The cash runway into Q2 2027 is relatively short for a Phase 3 programme, so financing and partnering developments are worth monitoring.

Company's press release (SEC filing): Eledon Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Eledon Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →